 Oxonic Acid
"Oxonic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antagonist of urate oxidase.
| Descriptor ID |
D010094
|
| MeSH Number(s) |
D03.383.931.640
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oxonic Acid".
Below are MeSH descriptors whose meaning is more specific than "Oxonic Acid".
This graph shows the total number of publications written about "Oxonic Acid" by people in this website by year, and whether "Oxonic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 | | 2006 | 0 | 2 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 2 | 2 | | 2013 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2018 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Oxonic Acid" by people in Profiles.
-
Yang J, Wang J, Zhou H, Wang Y, Huang H, Jin H, Lou Q, Shah RJ, Zhang X. Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone?for unresectable extrahepatic cholangiocarcinoma. Gastrointest Endosc. 2020 12; 92(6):1204-1212.e1.
-
Katsuda M, Miyazawa M, Ojima T, Katanuma A, Hakamada K, Sudo K, Asahara S, Endo I, Ueno M, Hara K, Yamada S, Fujii T, Satoi S, Ioka T, Ohira M, Akahori T, Kitano M, Nagano H, Furukawa M, Adachi T, Yamaue H. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy. Trials. 2019 Apr 27; 20(1):242.
-
Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Matsuyama Y, Unno M. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019 Feb 01; 49(2):190-194.
-
Akahori T, Sho M, Yanagimoto H, Satoi S, Nagai M, Nishiwada S, Nakagawa K, Nakamura K, Yamamoto T, Hirooka S, Yamaki S, Ikeda N. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Oncologist. 2019 06; 24(6):749-e224.
-
S?nchez-Lozada LG, Garc?a-Arroyo FE, Gonzaga G, Silverio O, Blas-Marron MG, Mu?oz-Jimenez I, Tapia E, Osorio-Alonso H, Madero M, Roncal-Jim?nez CA, Weiss I, Glaser J, Johnson RJ. Kidney Injury from Recurrent Heat Stress and Rhabdomyolysis: Protective Role of Allopurinol and Sodium Bicarbonate. Am J Nephrol. 2018; 48(5):339-348.
-
Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M, Tsuchida A, Unno M. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol. 2019 Feb; 54(2):194-203.
-
Garc?a-Arroyo FE, Gonzaga G, Mu?oz-Jim?nez I, Blas-Marron MG, Silverio O, Tapia E, Soto V, Ranganathan N, Ranganathan P, Vyas U, Irvin A, Ir D, Robertson CE, Frank DN, Johnson RJ, S?nchez-Lozada LG. Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. PLoS One. 2018; 13(8):e0202901.
-
Yanagimoto H, Toyokawa H, Sakai D, Wada H, Satoi S, Yamamoto T, Nagano H, Toyoda M, Ajiki T, Satake H, Tsuji A, Miyamoto A, Tsujie M, Takemura S, Yanagihara K, Ioka T. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202). Cancer Chemother Pharmacol. 2018 03; 81(3):461-468.
-
Satoi S, Fujii T, Yanagimoto H, Motoi F, Kurata M, Takahara N, Yamada S, Yamamoto T, Mizuma M, Honda G, Isayama H, Unno M, Kodera Y, Ishigami H, Kon M. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Ann Surg. 2017 02; 265(2):397-401.
-
Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Minoru T. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016 Aug; 23(8):480-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|